Background: Conventional medical therapies for neurodegenerative diseases primarily
target anti-inflammatory interventions, immune suppression of autoimmune pathologies, and, depending
on the diagnosed pathological mechanisms, neurotransmitter reuptake inhibition, among
other tactics. However, the incidence of neuroinflammatory pathologies appears to be progressively
increasing. The National Institutes of Health, National Institute of Environmental Health Sciences
in 2016, estimated that 5.4 million Americans were living with Alzheimer's. If no effective
solutions are found and implemented, within 30 years of this publication, according to data from
Harvard, more than 12 million Americans will suffer from neurodegenerative diseases.
Methods: Rather than investigating greater etiological depth, modern medicine seems to have been
designed to addressing obvious symptomologies to relieve suffering for as long as possible until
neuropathological progress inevitably wins in achieving complete functional disability and death.
Researchers are reporting herein evidence-based effective treatment therapies that are outside conventional
medical standard of care therapies.
Conclusion: These therapies are the result of a deeper exploration into etiological factors, including
an expanded understanding of the role of anaerobic pathologies in the etiology of neuroinflammatory
disorders and methods of reverting to a competent aerobic metabolism. Such therapies include
a liquid VMP35 MNC; a greater focus on viral mechanistic pathologies and their remission;
and understanding of the genetic basis for a loss of neurological interconnectivity and consequential
reward deficiencies in combination with neuronutrient deficiencies, enabling neuronutrient repletion
with nutrigenomic therapies such as the KB220Z.